Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Jacobson

Physician Assistant, Medical Fort Collins, CO Physician Assistant

NPI 1013959188 CMS profile 10754900

2121 E Harmony Rd, Suite 300, Fort Collins, CO 80528

Open in the dashboard

General payments

$130,958

192 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Jacobson of Fort Collins, CO is reported in the CMS Open Payments database as having received $130,958 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44,982 68
2024 General $53,199 83
2023 General $14,209 29
2022 General $13,830 6
2021 General $4,737 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Jacobson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Michael Jacobson were reported at $44,982. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Michael Jacobson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,737 $156 $41–$563 $132
2022 $13,830 $185 $55–$649 $149
2023 $14,209 $199 $58–$717 $160
2024 $53,199 $206 $62–$740 $164
2025 $44,982 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Inspire Medical Systems, Inc. $128,031 163 payments
  2. Respicardia, Inc. $2,063 10 payments
  3. Janssen Pharmaceuticals, Inc $288 8 payments
  4. MML US, Inc. $240 1 payment
  5. AstraZeneca Pharmaceuticals LP $121 1 payment
  6. Axsome Therapeutics, Inc. $56 2 payments
  7. Genentech USA, Inc. $46 2 payments
  8. Harmony Biosciences LLC $46 1 payment
  9. Biohaven Pharmaceutical Holding Company Ltd. $20 1 payment
  10. Insmed, Inc. $18 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $72,319 21 payments
  2. Honoraria $34,000 17 payments
  3. Travel and Lodging $16,217 76 payments
  4. Food and Beverage $8,421 78 payments
Products named General payments · program years 2021–2025
  1. INSPIRE $109,678 156 payments
  2. Inspire Upper Airway Stimulation System $18,353 7 payments
  3. remede System $2,063 10 payments
  4. INVEGA SUSTENNA $265 7 payments
  5. INVEGA TRINZA $265 7 payments
  6. ReActiv8 $240 1 payment
  7. Xolair $46 2 payments
  8. Wakix $46 1 payment
  9. Sunosi $31 1 payment
  10. Auvelity $26 1 payment
  11. Other $164 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

630

Median for Physician Assistant: 241

Drug cost

$37,310

Median for Physician Assistant: $4,110

Branded share of claims

23.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $15,169
Spiriva Handihaler Tiotropium Bromide Brand 13 $7,460
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 16 $5,044
Gabapentin Generic 171 $2,440
Albuterol Sulfate Hfa Albuterol Sulfate Brand 35 $1,570
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 62 $1,329
Modafinil Generic 18 $818
Azelastine Hcl Generic 28 $809
Trazodone Hcl Generic 93 $679
Montelukast Sodium Generic 40 $579

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$71,902

Medicare's payments for the services billed

Medicare patients

699

Average age 73

Services billed

1,048

326 women, 373 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Ischemic heart disease 26%
Depression 26%
Diabetes 23%
Atrial fibrillation 21%
Chronic kidney disease 20%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $111
$111 — —
INVEGA TRINZA
  • Janssen Pharmaceuticals, Inc $111
$111 — —
Xolair
  • Genentech USA, Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record